Suspected de novo heart failure in outpatient care: the REVOLUTION HF study

Cardiovascular mortality and morbidity in patients with T2D following initiation of SGLT2i versus other glucose-lowering drugs

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT2i Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure.

Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries

Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization:

Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)

Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

Dapagliflozin treatment of patients with CKD without diabetes across different albuminuria levels.

Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases

Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study